New FDA alert targets imported GLP-1 ingredients used in compounding
The alert applies to imported GLP-1 ingredients that compounding pharmacies rely on, and FDA says adulterated ingredients put the safety of the American public at risk.
The FDA has issued Import Alert 66-80, a directive telling its field divisions they may hold shipments of glucagon-like peptide-1 (GLP-1) receptor agonist bulk drug substances without physically examining them. The exception is manufacturers and products named on the alert's Green List [1].
The covered active pharmaceutical ingredients (APIs) include semaglutide, tirzepatide, liraglutide, exenatide and orforglipron, plus peptide and anti-diabetic product codes that also apply to retatrutide [1].
What FDA found
To assess the registered GLP-1 API makers supplying the U.S. market, FDA says it carried out onsite inspections and remote regulatory assessments of 48 sites, using records requests under section 704(a)(4) of the Food, Drug, and Cosmetic Act. Twenty-one percent of those 48 sites came back noncompliant under section 501 — either the records they turned over showed problems with current good manufacturing practice (CGMP), or the company did not answer the request in time [1].
The alert also describes "a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA's requests for records, and then deregister, all within a short period of time" [1].
FDA ties the alert to compounding. When approved GLP-1 medicines were in shortage, compounding of copies rose, and the ingredients came from plants in China, India and Europe. Drugs that meet the conditions of section 503A are exempt from CGMP rules, including the requirement to confirm an API meets impurity or potency specifications. So a weakness in the bulk substance may never be caught while the finished compounded product is being made, according to the alert [1]. The agency concludes that foreign-sourced GLP-1 APIs "should be considered for detention without physical examination (DWPE) based on the appearance of adulteration," adding that adulteration "puts the safety of the American public at risk" [1].
Which suppliers are exempt
The Green List names registered foreign manufacturers whose facilities and products FDA currently believes meet CGMP requirements. As of the alert's initial issuance, it includes one firm in Belgium, one in Canada and a long roster of firms in China. Listed ingredients include semaglutide, tirzepatide, liraglutide, exenatide and orforglipron [1].
The page shows a published date of August 21, 2026. A "major revision" described on it responds to a CDER Office of Compliance memo dated March 19, 2026. That revision added orforglipron API for three manufacturers and orforglipron SDD, a drug product intermediate, for one, and created a new product code for orforglipron, 61P[][]77. It also added four Hormone N.E.C. codes [1].
FDA notes the alert is guidance to field personnel about the manufacturers and products at issue and does not create rights for anyone or bind the agency or the public [1].
Why it matters for patients
The alert targets bulk ingredients entering the country, not the finished brand-name medicines a pharmacy dispenses. Ozempic, Wegovy and Rybelsus are made with semaglutide; Mounjaro and Zepbound with tirzepatide; Foundayo with orforglipron. Those approved products are not the subject of the alert [1].
Where it can be felt is in compounded GLP-1 drugs, which depend on imported API. If a shipment from a manufacturer not on the Green List is held, the supplier or pharmacy would need a listed source, or the manufacturer would need to be added to the list first [1]. The alert does not conclude that compounded products are inherently unsafe, and it offers no information about doses or which products to use.
Numbers that would show the alert's real-world reach are missing. The alert does not say how many GLP-1 API shipments have been detained, how long a detention usually lasts, or which compounders buy from unlisted manufacturers. None of that has been disclosed.
What happens next
A manufacturer seeking a place on the Green List can ask FDA to remove it from detention without physical examination. The alert recommends sending that material before shipping covered drugs, which FDA says may reduce delays at the port [1].
The documentation list is long: a certificate of analysis for the last ten GLP-1 API lots, or all of them if fewer than ten have been made; container labels; a customer list with names, addresses, FEI numbers and contacts; release specifications and test methods with scientific justification; a stability protocol and results; starting-material specifications; method validation or verification reports; contract lab names and addresses; process validation records; the master batch record plus the most recent batch record; an equipment list with qualification dates; all out-of-specification results, including phase 1 laboratory results; a list of standard operating procedures; a quality-unit organization chart; and five years of summaries covering complaints, adverse events, recalls and returns [1].
Submissions go to the Division of Import Operations, which forwards them to CDER for evaluation. A firm can also be dropped from the Green List later if FDA finds its products no longer comply with the law [1]. The alert sets no timeline for how long a review takes.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.